Skip to main content

Table 1 Summary of four cases

From: Significant risk factors for malignant transformation of ovarian endometrioma during dienogest treatment: a case report and retrospective study

 

Case 1

Case 2

Case 3

Case 4

Patient’s parity

Nullipara

Nullipara

Nullipara

Nullipara

Age at start of DNGT

43 years

44 years

42 years

44 years

Age at MT

44 years

46 years

42 years

46 years

Cyst size before DNGT

7 cm (left), 3 cm (right)

8 cm (left)

4 cm (left)

3 cm (left)

Cyst size at MT

7 cm (left), 3 cm (right)

5 cm (left)

7 cm (left), 2 cm (right)

3 cm (left), 2 cm (right)

Duration of DNGT

14 months

31 months

9 months

33 months

Operation for ovarian carcinoma

TAH, BSO, OM, PLA, PALA

LSO

TAH, BSO, OM, PLA, PALA

TAH, BSO, OM

Pathology

Clear cell carcinoma

Clear cell carcinoma

Clear cell carcinoma

Clear cell carcinoma

Origin of carcinoma

Left ovary

Left ovary

Left ovary

Right ovary

FIGO stage

1C1

1C3

1C1

1C1

Surgical history (age)

Bilateral LC (43 years)

Left-side LC (40 years)

No

No

Chemotherapy

TC for 6 cycles

TC for 3 cycles

TC for 6 cycles

TC for 6 cycles

Serum CA 125 at MT

515 U/ml

78.5 U/ml

42.4 U/ml

46.3 U/ml

  1. Abbreviations: BSO Bilateral salpingo-oophorectomy, CA 125 Cancer antigen 125, DNGT Dienogest therapy, FIGO International Federation of Gynecology and Obstetrics, LC Laparoscopic cystectomy, LSO Left salpingo-oophorectomy, MT Malignant transformation, OM Omentectomy, PALA Para-aortic lymphadenectomy, PLA Pelvic lymphadenectomy, RSO Right salpingo-oophorectomy, TAH Total abdominal hysterectomy, TC Paclitaxel and carboplatin